Back to search results

MPN PROGRESSion Registry: Understanding Myeloproliferative Neoplasms

This is an observational study, not a treatment trial, designed to better understand myeloproliferative neoplasms (MPNs). These are rare, chronic blood cancers like polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). Researchers will track your symptoms, treatments, and how your disease progresses over time. The goal is to gather real-world information from 5,000 participants to help improve care and research for people with MPNs. You may be eligible if you are an adult aged 18 or older with a confirmed MPN diagnosis, even if you've had a stem cell or bone marrow transplant.

Study design
This is an observational study aiming to enroll 5,000 participants. It is not testing a new intervention but rather collecting information over time.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed continuously from enrollment for a minimum of 5 years, with potential follow-up extending beyond 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07362225

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Recruiting
Not specifiedAges 18+Observational
MPN Research Foundation
~5,000 participants
Updated 2026-01-23 on ClinicalTrials.gov

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Time to Disease Progression
Measured over Assessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years for participants who remain active in the registry.

Conditions

Polycythemia Vera
ET (Essential Thrombocythemia)
Polycythemia Vera (PV)
Essential Thrombocythemia (ET)
Primary Myelofibrosis (MF)
Primary Myelofibrosis (PMF)
Myelofibrosis
Myelofibrosis (MF)
Myelofibrosis, Primary
Myelofibrosis, Post ET
Myelofibrosis, Post PV
Myelofibrosis (PMF)
Myelofibrosis，MF
Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Myelofibrosis Due to and Following Polycythemia Vera
Myelofibrosis Transformation in Essential Thrombocythemia
Myelofibrosis With High Molecular Risk Mutations
MF
Secondary Myelofibrosis
Secondary Myelofibrosis in Myeloproliferative Disease
Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
Post-Polycythemia Vera Myelofibrosis
Post-polycythemia Vera Myelofibrosis (PPV-MF)
Post-polycythemia Vera Myelofibrosis (Post-PV MF)
Post-polycythemia Vera Myelofibrosis(Post-PV MF)
Post-PV MF
Post-Essential Thrombocythemia Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)
Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Post-ET MF
Pre-fibrotic Myelofibrosis
Myeloproliferative Disorder
Myeloproliferative Disorders
Myeloproliferative Disorders (MPD)
Myeloproliferative Neoplasms (MPNs)
Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis
Myeloproliferative Neoplasm With 10% Blasts or Higher
Myeloproliferative Neoplasms
MPN
MPN (Myeloproliferative Neoplasms)
MPN-associated Myelofibrosis
Myeloproliferative Neoplasm, Unclassifiable
Myeloproliferative Neoplasm, Not Otherwise Specified
Accelerated Phase MPN
Accelerated Phase Myeloproliferative Neoplasm
Blast Phase MPN
Blast Phase Myeloproliferative Neoplasm
Thrombocythemia Myelofibrosis (PET-MF)
Thrombocythemia, Essential
Thrombocythemia, Hemorrhagic
Agnogenic Myeloid Metaplasia
Chronic Idiopathic Myelofibrosis
Idiopathic Myelofibrosis
MDS/MPN Crossover Syndromes

Explore related trials

Accelerated Phase Myeloproliferative NeoplasmAcute Myeloid LeukemiaBlast Phase Myeloproliferative NeoplasmEssential ThrombocythemiaMiller-Dieker SyndromeMyeloproliferative neoplasm unclassifiablePolycythemia VeraPrefibrotic Primary MyelofibrosisPrimary MyelofibrosisSecondary Myelofibrosis

Where it's being run

2 sites across 2 states
Illinois1
New York1

Study leadership

  • Raajit Rampal, MD, PhD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

Stephanie Scobey, MPN, BS, RN
[email protected]
847-449-5307
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 18 years or older at the time of enrollment.
Confirmed diagnosis of a myeloproliferative neoplasm (MPN), including one or more of the following subtypes, according to WHO 2022 criteria, including patients originally diagnosed with one of these conditions but who have received one or more stem cell transplants (SCTs) or bone marrow transplants (BMTs):
Polycythemia vera (PV)
Essential thrombocythemia (ET)
Primary myelofibrosis (PMF)
Secondary myelofibrosis (post-ET or post-PV MF)
Pre-fibrotic primary myelofibrosis (pre-PMF)
Myeloproliferative neoplasm-unclassifiable (MPN-U)
Myeloproliferative neoplasm, accelerated phase (MPN-AP)
Myeloproliferative neoplasm, blast phase (MPN-BP)
Post-MPN acute myeloid leukemia (AML)
Myelodysplastic syndrome (MDS)/MPN overlap syndrome
Myeloproliferative neoplasm, blast phase (MPN-BP)
Ability to provide informed consent electronically or through a legally authorized representative.
Willingness to share health information, including electronic health records (EHR), laboratory values, and survey responses.
Willingness to complete periodic patient-reported outcome (PRO) surveys and symptom tracking assessments.

Exclusion

Individuals under 18 years of age.
Inability to provide informed consent, either directly or through a legally authorized representative.
Currently enrolled in an interventional clinical trial where participation would interfere with the ability to participate in this observational registry (based on investigator or sponsor judgment).
Any condition that, in the judgment of the study team, would make participation in the registry infeasible or unsafe.

What this trial measures

  • Time to Disease ProgressionAssessed continuously from enrollment over a minimum of 5 years per participant, with extended follow-up beyond 10 years for participants who remain active in the registry.

    Time from enrollment to the first documented disease progression event, defined as transformation between MPN subtypes (for example, essential thrombocythemia or polycythemia vera to myelofibrosis), development of accelerated-phase MPN (MPN-AP), progression to blast phase (MPN-BP), or meeting updated World Health Organization (WHO) or International Working Group for Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria for disease progression. This outcome measures the rate and timing of disease evolution over time and evaluates associations with treatments, exposures, and clinical risk factors among adults diagnosed with MPNs.